1
|
Rosenfeld AB, Biasi G, Petasecca M, Lerch MLF, Villani G, Feygelman V. Semiconductor dosimetry in modern external-beam radiation therapy. Phys Med Biol 2020; 65:16TR01. [PMID: 32604077 DOI: 10.1088/1361-6560/aba163] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
2
|
Ruiz-Arrebola S, Fabregat-Borrás R, Rodríguez E, Fernández-Montes M, Pérez-Macho M, Ferri M, García A, Cardenal J, Pacheco MT, Anchuelo J, Tornero-López AM, Prada PJ, Guirado D. Characterization of microMOSFET detectors for in vivo dosimetry in high-dose-rate brachytherapy with 192 Ir. Med Phys 2020; 47:2242-2253. [PMID: 32031263 DOI: 10.1002/mp.14080] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 12/23/2019] [Accepted: 12/23/2019] [Indexed: 11/06/2022] Open
Abstract
PURPOSE The objective of this study was to characterize the Best Medical Canada microMOSFET detectors for their application in in vivo dosimetry for high-dose-rate brachytherapy (HDRBT) with 192 Ir. We also developed a mathematical model to correct dependencies under the measurement conditions of these detectors. METHODS We analyzed the linearity, reproducibility, and interdetector variability and studied the microMOSFET response dependence on temperature, source-detector distance, and angular orientation of the receptor with respect to the source. The correction model was applied to 19 measurements corresponding to five simulated treatments in a custom phantom specifically designed for this purpose. RESULTS The detectors (high bias applied in all measurements) showed excellent linearity up to 160 Gy. The response dependence on source-detector distance varied by (8.65 ± 0.06)% (k = 1) for distances between 1 and 7 cm, and the variation with temperature was (2.24 ± 0.05)% (k = 1) between 294 and 310 K. The response difference due to angular dependence can reach (10.3 ± 1.3)% (k = 1). For the set of measurements analyzed, regarding angular dependences, the mean difference between administered and measured doses was -4.17% (standard deviation of 3.4%); after application of the proposed correction model, the mean difference was -0.1% (standard deviation of 2.2%). For the treatments analyzed, the average difference between calculations and measures was 4.7% when only the calibration coefficient was used, but it is reduced to 0.9% when the correction model is applied. CONCLUSION Important response dependencies of microMOSFET detectors used for in vivo dosimetry in HDRBT treatments, especially the angular dependence, can be adequately characterized by a correction model that increases the accuracy of this system in clinical applications.
Collapse
Affiliation(s)
- Samuel Ruiz-Arrebola
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Rosa Fabregat-Borrás
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Eduardo Rodríguez
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Manuel Fernández-Montes
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Mercedes Pérez-Macho
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - María Ferri
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Ana García
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Juan Cardenal
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - María T Pacheco
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Javier Anchuelo
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Ana M Tornero-López
- Servicio de Radiofísica y Protección Radiológica, Hospital Universitario Dr. Negrín, Gran Canaria, Spain
| | - Pedro J Prada
- Marqués de Valdecilla University Hospital, Department of Radiation Oncology and Radiophysics, Santander, Spain
| | - Damián Guirado
- Instituto de Investigación Biosanitaria (ibs.GRANADA), Hospital Clínico Universitario San Cecilio, Unidad de Radiofísica, Granada, Spain.,CIBER de Epidemiología y Salud Pública (CIBERESP), Granada, Spain
| |
Collapse
|
3
|
Jamalludin Z, Jong W, Malik R, Rosenfeld A, Ung N. Evaluation of rectal dose discrepancies between planned and in vivo dosimetry using MOSkin detector and PTW 9112 semiconductor probe during 60Co HDR CT-based intracavitary cervix brachytherapy. Phys Med 2020; 69:52-60. [DOI: 10.1016/j.ejmp.2019.11.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 11/26/2019] [Accepted: 11/29/2019] [Indexed: 10/25/2022] Open
|
4
|
Jamalludin Z, Jong WL, Ho GF, Rosenfeld AB, Ung NM. In vivo dosimetry using MOSkin detector during Cobalt-60 high-dose-rate (HDR) brachytherapy of skin cancer. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2019; 42:1099-1107. [PMID: 31650362 DOI: 10.1007/s13246-019-00809-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Accepted: 10/16/2019] [Indexed: 01/10/2023]
Abstract
The MOSkin, a metal-oxide semiconductor field-effect transistor based detector, is suitable for evaluating skin dose due to its water equivalent depth (WED) of 0.07 mm. This study evaluates doses received by target area and unavoidable normal skin during a the case of skin brachytherapy. The MOSkin was evaluated for its feasibility as detector of choice for in vivo dosimetry during skin brachytherapy. A high-dose rate Cobalt-60 brachytherapy source was administered to the tumour located at the medial aspect of the right arm, complicated with huge lymphedema thus limiting the arm motion. The source was positioned in the middle of patients' right arm with supine, hands down position. A 5 mm lead and 5 mm bolus were sandwiched between the medial aspect of the arm and lateral chest to reduce skin dose to the chest. Two calibrated MOSkin detectors were placed on the target and normal skin area for five treatment sessions for in vivo dose monitoring. The mean dose to the target area ranged between 19.9 and 21.1 Gy and was higher in comparison with the calculated dose due to contribution of backscattered dose from lead. The mean measured dose at normal skin chest area was 1.6 Gy (1.3-1.9 Gy), less than 2 Gy per fraction. Total dose in EQD2 received by chest skin was much lower than the recommended skin tolerance. The MOSkin detector presents a reliable real-time dose measurement. This study has confirmed the applicability of the MOSkin detector in monitoring skin dose during brachytherapy treatment due to its small sensitive volume and WED 0.07 mm.
Collapse
Affiliation(s)
- Z Jamalludin
- Medical Physics Unit, University of Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia
- Department of Clinical Oncology, University of Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - W L Jong
- Department of Clinical Oncology, University of Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - G F Ho
- Department of Clinical Oncology, University of Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - A B Rosenfeld
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - N M Ung
- Department of Clinical Oncology, University of Malaya Medical Centre, 59100, Kuala Lumpur, Malaysia.
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.
| |
Collapse
|
5
|
Jamalludin Z, Jong WL, Abdul Malik R, Rosenfeld A, Ung NM. Characterization of MOSkin detector for in vivo dose verification during Cobalt-60 high dose-rate intracavitary brachytherapy. Phys Med 2019; 58:1-7. [PMID: 30824140 DOI: 10.1016/j.ejmp.2019.01.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 12/12/2018] [Accepted: 01/08/2019] [Indexed: 10/27/2022] Open
Abstract
In vivo dosimetry in high dose-rate (HDR) intracavitary brachytherapy (ICBT) is important for assessing the true dose received by surrounding organs at risk during treatment. It also serves as part of the treatment delivery quality assurance and verification program with the use of a suitable dosimeter. Such a dosimeter should be characterized under brachytherapy conditions before clinical application to ensure the accuracy of in vivo measurement. In this study, a MOSFET-based detector, MOSkin, was calibrated and characterized under HDR Cobalt-60 (Co-60) brachytherapy source. MOSkin possessed the major advantages of having small physical and dosimetric sizes of 4.8 × 10-6 mm3 with the ability to provide real-time measurements. Using solid water and polymethyl methacrylate (PMMA) phantom, the detectors' reproducibility, linearity, angular and distance dependency was tested for its suitability as an in vivo detector. Correction factors to account for differences in depth measurements were determined. The MOSkin detector showed a reliable response when tested under Co-60 brachytherapy range of doses with an excellent linearity of R2 = 0.9997 and acceptable reproducibility. A phantom verification study was also conducted to verify the differences between MOSkin responses and treatment planning (TPS) calculated doses. By taking into account several correction factors, deviations ranging between 0.01 and 0.4 Gy were found between MOSkin measured and TPS doses at measurement distance of 20-55 mm. The use of MOSkin as the dosimeter of choice for in vivo dosimetry under Co-60 brachytherapy condition is feasible.
Collapse
Affiliation(s)
- Zulaikha Jamalludin
- Department of Clinical Oncology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia; Medical Physics Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
| | - Wei Loong Jong
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Rozita Abdul Malik
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Anatoly Rosenfeld
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - Ngie Min Ung
- Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
| |
Collapse
|
6
|
In vivo dose verification method in catheter based high dose rate brachytherapy. Phys Med 2017; 44:1-10. [DOI: 10.1016/j.ejmp.2017.11.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2017] [Revised: 11/03/2017] [Accepted: 11/04/2017] [Indexed: 11/19/2022] Open
|
7
|
Carrara M, Tenconi C, Mazzeo D, Romanyukha A, Borroni M, Pignoli E, Cutajar D, Petasecca M, Lerch M, Bucci J, Gambarini G, Cerrotta A, Fallai C, Rosenfeld A. Study of the correlation between rectal wall in vivo dosimetry performed with MOSkins and implant modification during TRUS-guided HDR prostate brachytherapy. RADIAT MEAS 2017. [DOI: 10.1016/j.radmeas.2017.03.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Semiconductor real-time quality assurance dosimetry in brachytherapy. Brachytherapy 2017; 17:133-145. [PMID: 28964727 DOI: 10.1016/j.brachy.2017.08.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 08/22/2017] [Accepted: 08/28/2017] [Indexed: 11/23/2022]
Abstract
With the increase in complexity of brachytherapy treatments, there has been a demand for the development of sophisticated devices for delivery verification. The Centre for Medical Radiation Physics (CMRP), University of Wollongong, has demonstrated the applicability of semiconductor devices to provide cost-effective real-time quality assurance for a wide range of brachytherapy treatment modalities. Semiconductor devices have shown great promise to the future of pretreatment and in vivo quality assurance in a wide range of brachytherapy treatments, from high-dose-rate (HDR) prostate procedures to eye plaque treatments. The aim of this article is to give an insight into several semiconductor-based dosimetry instruments developed by the CMRP. Applications of these instruments are provided for breast and rectal wall in vivo dosimetry in HDR brachytherapy, urethral in vivo dosimetry in prostate low-dose-rate (LDR) brachytherapy, quality assurance of HDR brachytherapy afterloaders, HDR pretreatment plan verification, and real-time verification of LDR and HDR source dwell positions.
Collapse
|
9
|
Carrara M, Romanyukha A, Tenconi C, Mazzeo D, Cerrotta A, Borroni M, Cutajar D, Petasecca M, Lerch M, Bucci J, Richetti A, Presilla S, Fallai C, Gambarini G, Pignoli E, Rosenfeld A. Clinical application of MOSkin dosimeters to rectal wall in vivo dosimetry in gynecological HDR brachytherapy. Phys Med 2017; 41:5-12. [DOI: 10.1016/j.ejmp.2017.05.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Revised: 04/27/2017] [Accepted: 05/01/2017] [Indexed: 10/19/2022] Open
|
10
|
Legge K, Greer PB, O'Connor DJ, Wilton L, Richardson M, Hunter P, Wilfert A, Martin J, Rosenfeld A, Cutajar D. Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement. Radiat Oncol 2017; 12:41. [PMID: 28241841 PMCID: PMC5327549 DOI: 10.1186/s13014-017-0781-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 02/10/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND MOSFET dosimetry is a method that has been used to measure in-vivo doses during brachytherapy treatments and during linac based radiotherapy treatment. Rectal displacement devices (RDDs) allow for safe dose escalation for prostate cancer treatment. This study used dual MOSkin detectors to assess real-time in vivo rectal wall dose in patients with an RDD in place during a high dose prostate stereotactic body radiation therapy (SBRT) boost trial. METHODS The PROMETHEUS study commenced in 2014 and provides a prostate SBRT boost dose with a RDD in place. Twelve patients received two boost fractions of 9.5-10 Gy each delivered to the prostate with a dual arc volumetric modulated arc therapy (VMAT) technique. Two MOSkins in a face-to-face arrangement (dual MOSkin) were used to decrease angular dependence. A dual MOSkin was attached to the anterior surface of the Rectafix and read out at 1 Hz during each treatment. The planned dose at each measurement point was exported from the planning system and compared with the measured dose. The root mean square error normalised to the total planned dose was calculated for each measurement point and treatment arc for the entire course of treatment. RESULTS The average difference between the measured and planned doses over the whole course of treatment for all arcs measured was 9.7% with a standard deviation of 3.6%. The cumulative MOSkin reading was lower than the total planned dose for 64% of the arcs measured. The average difference between the final measured and final planned doses for all arcs measured was 3.4% of the final planned dose, with a standard deviation of 10.3%. CONCLUSIONS MOSkin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.
Collapse
Affiliation(s)
- Kimberley Legge
- University of Newcastle, University Drive, Callaghan, 2308, NSW, Australia.
| | - Peter B Greer
- University of Newcastle, University Drive, Callaghan, 2308, NSW, Australia.,Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | - Daryl J O'Connor
- University of Newcastle, University Drive, Callaghan, 2308, NSW, Australia
| | - Lee Wilton
- Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | - Matthew Richardson
- Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | - Perry Hunter
- Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | - Alex Wilfert
- Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | - Jarad Martin
- Calvary Mater Newcastle, Cnr Edith and Platt Streets, Waratah, 2298, NSW, Australia
| | | | - Dean Cutajar
- University of Wollongong, Wollongong, 2522, NSW, Australia
| |
Collapse
|
11
|
Carrara M, Tenconi C, Rossi G, Borroni M, Cerrotta A, Grisotto S, Cusumano D, Pappalardi B, Cutajar D, Petasecca M, Lerch M, Gambarini G, Fallai C, Rosenfeld A, Pignoli E. In vivo rectal wall measurements during HDR prostate brachytherapy with MOSkin dosimeters integrated on a trans-rectal US probe: Comparison with planned and reconstructed doses. Radiother Oncol 2016; 118:148-53. [DOI: 10.1016/j.radonc.2015.12.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 12/22/2015] [Accepted: 12/27/2015] [Indexed: 11/26/2022]
|
12
|
Safavi-Naeini M, Han Z, Alnaghy S, Cutajar D, Petasecca M, Lerch MLF, Franklin DR, Bucci J, Carrara M, Zaider M, Rosenfeld AB. BrachyView, a novel in-body imaging system for HDR prostate brachytherapy: Experimental evaluation. Med Phys 2015; 42:7098-107. [DOI: 10.1118/1.4935866] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|